BioDelivery Sciences International (BDSI) Receives Analyst Rating

BioDelivery Sciences International (BDSI) : 7 analysts are covering BioDelivery Sciences International (BDSI) and their average rating on the stock is 1.57, which is read as a Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

BioDelivery Sciences International (BDSI) : Currently there are 7 street experts covering BioDelivery Sciences International (BDSI) stock. The most bullish and bearish price target for the stock is $13 and $4 respectively for the short term. The average price target of all the analysts comes to $7. The estimated standard deviation from the target is $3.21.


BioDelivery Sciences International (NASDAQ:BDSI): The stock opened in the green at $2.42 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $2.4201 and a low of $2.33 for the day. The stock did not find buyers even at the lows and closed at $2.36 recording a loss of -2.48%. 545,231 shares exchanged hands during the trading day. The stock had closed at $2.42 in the previous days trading.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.